Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

The Alzheimer’s disease biomarker market is seeing steady growth, supported by rising Alzheimer’s and dementia prevalence and greater emphasis on early, accurate diagnosis. Advances in blood-based p-tau and amyloid-beta assays are improving accessibility by offering less invasive alternatives to cerebrospinal fluid testing and PET imaging. The trend is favorable for companies developing and commercializing biomarker-based diagnostic tools, though the article provides no market-size or revenue figures.

Analysis

The investable implication is less a standalone diagnostics-revenue opportunity than a reduction in the diagnostic bottleneck for disease-modifying Alzheimer’s therapies. Wider, lower-cost pre-screening can enlarge the addressable treated population for Eli Lilly (LLY) and Biogen (BIIB), but only if positive blood tests convert into reimbursed confirmatory imaging and then into infusion capacity. Over the next 6-18 months, LLY is better positioned to monetize any increase in patient identification because its commercial scale and treatment momentum can turn incremental diagnosis into volume; BIIB remains more dependent on execution and payer acceptance.

The clearest second-order losers are PET-imaging and cerebrospinal-fluid testing volumes at the margin, although blood assays are more likely to become a triage layer than a full replacement in the near term. Quest Diagnostics (DGX) and Labcorp (LH) could capture incremental testing volume through national lab distribution, but the earnings sensitivity is likely immaterial until payer coverage broadens and test ordering moves beyond specialist neurology practices. Large instrument vendors such as Roche (RHHBY) and Abbott (ABT) have distribution advantages, yet biomarker commoditization may limit pricing power relative to the value captured by therapeutic manufacturers.

Consensus may overestimate the speed of adoption: clinical validity does not ensure reimbursement, and positive predictive value deteriorates when testing broad, low-prevalence populations. The key 1-3 month catalysts are Medicare/commercial-payer coverage decisions, professional-society guidance on confirmatory testing, and evidence that blood-test positivity converts to treatment starts. The thesis is falsified if LLY treatment-start growth fails to accelerate despite broader testing availability, or if payers require PET/CSF confirmation in nearly all cases, preserving the existing capacity constraint.

Key Decisions for Investors

• Maintain a 6-18 month overweight bias in LLY versus BIIB: use LLY/BIIB as a relative-value expression of diagnostic-access expansion, with the spread thesis invalidated by BIIB gaining disproportionate new-start share or LLY cutting treatment-volume guidance.
• Do not initiate a standalone long in DGX or LH solely on Alzheimer’s blood-testing adoption; set an alert for disclosed reimbursed test volumes, payer contracts, or biomarker-testing revenue that can support at least a 1% annual revenue contribution before underwriting earnings upside.
• Monitor RHHBY and ABT for assay-placement disclosures rather than treating the theme as a near-term catalyst; their diagnostic franchises are diversified enough that biomarker adoption is unlikely to move consolidated estimates without evidence of premium pricing or unusually rapid utilization.
• For healthcare exposure, favor a modest long LLY / short BIIB pair over broad biotech beta for the next 6-12 months; target approximately 2:1 upside/downside, and reduce if reimbursement policy preserves mandatory PET/CSF confirmation or infusion-site capacity becomes the binding constraint.